 etoposid therapi testicular cancer past decad dramat stride treatment metastat testicular cancer earli cisplatin vinblastin bleomycin pvb durabl complet remiss CR treat patient earli drug single-ag activ cisplatin-refractori patient preclin data synergi cisplatin etoposid two-drug combin use salvag therapi patient further evalu etoposid part initi therapi southeastern cancer studi group secsg pvb bleomycin cisplatin bep untreat patient metastat germ cell tumor bep toxic superior pbv patient advanc diseas dose schedul etoposid patient use avenu treatment high-dos etoposid carboplatin drug-refractori patient durabl CR cohort treat patient part initi salvag therapi schedul depend etoposid small cell lung cancer daili oral administr etoposid patient refractori previou etoposid therapi object respons rate summari etoposid integr part treatment regimen testi cancer incorpor innov dose schedul combin etoposid therapeut index diseas